The Korean Journal of Gastroenterology (대한소화기학회지)

The Korean Society of Gastroenterology (대한소화기학회)
권호 표지
DOI QR코드

DOI QR Code

Functional Dyspepsia

기능성 소화불량증

  • Oh, Jung Hwan (Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Kwon, Joong Goo (Department of Internal Medicine, Daegu Catholic University School of Medicine)
  • 오정환 (가톨릭대학교 의과대학 내과학교실) ;
  • 권중구 (대구가톨릭대학교 의과대학 내과학교실)
  • Received : 2018.12.28
  • Accepted : 2019.02.07
  • Published : 2019.02.25
⟨ Previous Next ⟩

Abstract

Dyspepsia is a common problem, and when dyspeptic symptoms develop within a short period of time, organic diseases such as gastroesophageal reflux disease, peptic ulcer diseases, pancreatoduodenal diseases, and gastrointestinal cancers should be suspected. Furthermore, functional dyspepsia (FD) should be considered if chronic or recurrent symptoms persist after eliminating underlying disease. FD is classified as epigastric pain syndrome (EPS) or postprandial distress syndrome (PDS), but these two conditions may overlap. Patients with the EPS subtype can be treated with proton pump inhibitors (PPIs), whereas patients with the PDS subtype may be managed primarily with prokinetics, and patients with EPS and PDS can be co-administered PPIs and prokinetics. Helicobacter pylori eradication therapy can be administered on a test-and-treat basis when PPIs and prokinetics are ineffective or to younger patients with chronic dyspepsia, and tricyclic antidepressants can be used as a secondary treatment because they are effective in patients with the EPS subtype. In addition, because the pathophysiology of FD is diverse, dietary education and stress management are required in addition to medical therapy, and should substantially aid treatment and long-term management. Here, we introduce and summarize recently published guidelines for the treatment of FD.

Keywords

References

  1. Lee H, Jung HK, Huh KC, Functional Dyspepsia Study Group in the Korean Society of Neurogastroenterology and Motility. Current status of functional dyspepsia in Korea. Korean J Intern Med 2014;29:156-165. https://doi.org/10.3904/kjim.2014.29.2.156
  2. Jung HK, Keum BR, Jo YJ, et al. Diagnosis of functional dyspepsia: a systematic review. Korean J Gastroenterol 2010;55:296-307. https://doi.org/10.4166/kjg.2010.55.5.296
  3. Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology 2016;150:1380-1392. https://doi.org/10.1053/j.gastro.2016.02.011
  4. Jung KW. Understanding the Rome IV: gastroduodenal disorders. Korean J Med 2017;92:362-365. https://doi.org/10.3904/kjm.2017.92.4.362
  5. Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol 2017;112:988-1013. https://doi.org/10.1038/ajg.2017.154
  6. Li XB, Liu WZ, Ge ZZ, Chen XY, Shi Y, Xiao SD. Helicobacter pylori "test-and-treat" strategy is not suitable for the management of patients with uninvestigated dyspepsia in Shanghai. Scand J Gastroenterol 2005;40:1028-1031. https://doi.org/10.1080/00365520510023206
  7. Liou JM, Lin JT, Wang HP, et al. The optimal age threshold for screening upper endoscopy for uninvestigated dyspepsia in Taiwan, an area with a higher prevalence of gastric cancer in young adults. Gastrointest Endosc 2005;61:819-825. https://doi.org/10.1016/S0016-5107(05)00366-4
  8. Chen SL, Gwee KA, Lee JS, et al. Systematic review with meta-analysis: prompt endoscopy as the initial management strategy for uninvestigated dyspepsia in Asia. Aliment Pharmacol Ther 2015;41:239-252. https://doi.org/10.1111/apt.13028
  9. Miwa H, Kusano M, Arisawa T, et al. Evidence-based clinical practice guidelines for functional dyspepsia. J Gastroenterol 2015;50:125-139. https://doi.org/10.1007/s00535-014-1022-3
  10. Miwa H, Ghoshal UC, Fock KM, et al. Asian consensus report on functional dyspepsia. J Gastroenterol Hepatol 2012;27:626-641. https://doi.org/10.1111/j.1440-1746.2011.07037.x
  11. Jee SR, Jung HK, Min BH, et al. Guidelines for the treatment of functional dyspepsia. Korean J Gastroenterol 2011;57:67-81. https://doi.org/10.4166/kjg.2011.57.2.67
  12. Shin CM. Diet and nutritional management in functional gastrointestinal disorder: functional dyspepsia. Korean J Med 2016;90:98-104. https://doi.org/10.3904/kjm.2016.90.2.98
  13. Pinto-Sanchez MI, Yuan Y, Hassan A, Bercik P, Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev 2017;11:CD011194.
  14. Lee HH, Jung HK, Choi MG. Guideline recommendation for endpoints used in clinical trials for functional dyspepsia. Korean J Gastroenterol 2018;72:170-178. https://doi.org/10.4166/kjg.2018.72.4.170
  15. Lacy BE, Talley NJ, Locke GR 3rd, et al. Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther 2012;36:3-15. https://doi.org/10.1111/j.1365-2036.2012.05128.x
  16. Park KH, Pai J, Song DG, et al. Ranitidine-induced anaphylaxis: clinical features, cross-reactivity, and skin testing. Clin Exp Allergy 2016;46:631-639. https://doi.org/10.1111/cea.12708
  17. Regan LA, Hoffman RS, Nelson LS. Slower infusion of metoclopramide decreases the rate of akathisia. Am J Emerg Med 2009;27:475-480. https://doi.org/10.1016/j.ajem.2008.03.044
  18. Tura P, Erdur B, Aydin B, Turkcuer I, Parlak I. Slow infusion metoclopramide does not affect the improvement rate of nausea while reducing akathisia and sedation incidence. Emerg Med J 2012;29:108-112. https://doi.org/10.1136/emj.2010.094367
  19. Shin HW, Kim MJ, Kim JS, Lee MC, Chung SJ. Levosulpiride-induced movement disorders. Mov Disord 2009;24:2249-2253. https://doi.org/10.1002/mds.22805
  20. Bang CS, Kim JH, Baik GH, et al. Mosapride treatment for functional dyspepsia: a meta-analysis. J Gastroenterol Hepatol 2015;30:28-42. https://doi.org/10.1111/jgh.12662
  21. Yoon H, Lee DH, Lee YH, et al. Efficacy and safety of UI05MSP015CT in functional dyspepsia: a randomized, controlled trial. Gut Liver 2018;12:516-522. https://doi.org/10.5009/gnl17416
  22. Yang YJ, Bang CS, Baik GH, et al. Prokinetics for the treatment of functional dyspepsia: bayesian network meta-analysis. BMC Gastroenterol 2017;17:83. https://doi.org/10.1186/s12876-017-0639-0
  23. Jung HK, Lee KJ, Choi MG, et al. Efficacy of DA-9701 (Motilitone) in functional dyspepsia compared to pantoprazole: a multicenter, randomized, double-blind, non-inferiority study. J Neurogastroenterol Motil 2016;22:254-263. https://doi.org/10.5056/jnm15178
  24. Pittayanon R, Yuan Y, Bollegala NP, et al. Prokinetics for functional dyspepsia: a systematic review and meta-analysis of randomized control trials. Am J Gastroenterol 2019;114:233-243. https://doi.org/10.1038/s41395-018-0258-6
  25. Suzuki H, Moayyedi P. Helicobacter pylori infection in functional dyspepsia. Nat Rev Gastroenterol Hepatol 2013;10:168-174. https://doi.org/10.1038/nrgastro.2013.9
  26. Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015;64:1353-1367. https://doi.org/10.1136/gutjnl-2015-309252
  27. Liu WZ, Xie Y, Lu H, et al. Fifth Chinese national consensus report on the management of Helicobacter pylori infection. Helicobacter 2018;23:e12475. https://doi.org/10.1111/hel.12475
  28. Mahachai V, Vilaichone RK, Pittayanon R, et al. Helicobacter pylori management in ASEAN: the Bangkok consensus report. J Gastroenterol Hepatol 2018;33:37-56. https://doi.org/10.1111/jgh.13911
  29. Mazzoleni LE, Sander GB, Francesconi CF, et al. Helicobacter pylori eradication in functional dyspepsia: HEROES trial. Arch Intern Med 2011;171:1929-1936. https://doi.org/10.1001/archinternmed.2011.533
  30. Lee SY. Endoscopic gastritis, serum pepsinogen assay, and Helicobacter pylori infection. Korean J Intern Med 2016;31:835-844. https://doi.org/10.3904/kjim.2016.166
  31. Lan L, Yu J, Chen YL, et al. Symptom-based tendencies of Helicobacter pylori eradication in patients with functional dyspepsia. World J Gastroenterol 2011;17:3242-3247. https://doi.org/10.3748/wjg.v17.i27.3242
  32. Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology 2017;153:420-429. https://doi.org/10.1053/j.gastro.2017.04.022
  33. Talley NJ, Locke GR, Saito YA, et al. Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study. Gastroenterology 2015;149:340-349.e2. https://doi.org/10.1053/j.gastro.2015.04.020
  34. Lu Y, Chen M, Huang Z, Tang C. Antidepressants in the treatment of functional dyspepsia: a systematic review and meta-analysis. PLoS One 2016;11:e0157798. https://doi.org/10.1371/journal.pone.0157798
  35. Tack J, Ly HG, Carbone F, et al. Efficacy of mirtazapine in patients with functional dyspepsia and weight loss. Clin Gastroenterol Hepatol 2016;14:385-392.e4. https://doi.org/10.1016/j.cgh.2015.09.043
  36. Tack J, Janssen P, Masaoka T, Farre R, Van Oudenhove L. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol 2012;10:1239-1245. https://doi.org/10.1016/j.cgh.2012.06.036
  37. Matsueda K, Hongo M, Tack J, Saito Y, Kato H. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut 2012;61:821-828. https://doi.org/10.1136/gutjnl-2011-301454
  38. Jaafar MH, Safi SZ, Tan MP, Rampal S, Mahadeva S. Efficacy of rebamipide in organic and functional dyspepsia: a systematic review and meta-analysis. Dig Dis Sci 2018;63:1250-1260. https://doi.org/10.1007/s10620-017-4871-9
  39. Holtmann G, Gschossmann J, Karaus M, et al. Randomised double-blind comparison of simethicone with cisapride in functional dyspepsia. Aliment Pharmacol Ther 1999;13:1459-1465. https://doi.org/10.1046/j.1365-2036.1999.00644.x
  40. Holtmann G, Gschossmann J, Mayr P, Talley NJ. A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia. Aliment Pharmacol Ther 2002;16:1641-1648. https://doi.org/10.1046/j.1365-2036.2002.01322.x
  41. Gudjonsson H, Oddsson E, Bjornsson S, et al. Efficacy of sucralfate in treatment of non-ulcer dyspepsia. A double-blind placebo-controlled study. Scand J Gastroenterol 1993;28:969-972. https://doi.org/10.3109/00365529309098293
  42. Kairaluoma MI, Hentilae R, Alavaikko M, et al. Sucralfate versus placebo in treatment of non-ulcer dyspepsia. Am J Med 1987;83:51-55. https://doi.org/10.1016/0002-9343(87)90828-X
  43. Moayyedi P, Soo S, Deeks J, et al. Systematic review: antacids, H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia. Aliment Pharmacol Ther 2003;17:1215-1227. https://doi.org/10.1046/j.1365-2036.2003.01575.x

Cited by

  1. 내장감각과민의 침구 치료에 대한 실험연구 현황: PubMed를 중심으로 vol.36, pp.2, 2019, https://doi.org/10.14406/acu.2019.006
  2. 한약재 함유 소화효소제품 복용에 대한 소비자들의 체험에 관한 질적 연구 vol.41, pp.1, 2019, https://doi.org/10.22246/jikm.2020.41.1.14
  3. 기능성 위장관 질환의 한의학적 치료 연구전략 수립을 위한 연구 동향 분석 vol.29, pp.1, 2021, https://doi.org/10.14374/hfs.2021.29.1.57
  4. The Effect of Proton Pump Inhibitor and Prokinetics Combination Therapy for Functional Dyspepsia vol.77, pp.4, 2021, https://doi.org/10.4166/kjg.2021.060
  5. 기능성 소화불량에 대한 사군자탕의 치료효과 - 체계적 문헌고찰과 메타분석 vol.42, pp.3, 2019, https://doi.org/10.22246/jikm.2021.42.3.259